0001193125-20-307956.txt : 20201202 0001193125-20-307956.hdr.sgml : 20201202 20201202092458 ACCESSION NUMBER: 0001193125-20-307956 CONFORMED SUBMISSION TYPE: RW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201202 DATE AS OF CHANGE: 20201202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: RW SEC ACT: SEC FILE NUMBER: 333-239484 FILM NUMBER: 201362536 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 302-842-8450 MAIL ADDRESS: STREET 1: 2 RIGHTER PARKWAY, SUITE 200 CITY: WILMINGTON STATE: DE ZIP: 19803 RW 1 d75271drw.htm RW RW

December 2, 2020

BY EDGAR TRANSMISSION

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

Re:    BioSpecifics Technologies Corp.

Request to Withdraw Registration Statement on Form S-3

File No. 333-239484

Ladies and Gentlemen:

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Act”), BioSpecifics Technologies Corp. (the “Company”) respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s Registration Statement on Form S-3 (File No. 333-239484), together with all exhibits and amendments thereto (collectively, the “Registration Statement”), filed with the Commission on June 26, 2020, subsequently amended by Amendment No. 1 filed with the Commission on July 15, 2020 and declared effective on July 17, 2020.

On December 2, 2020, pursuant to the Agreement and Plan of Merger, dated as of October 19, 2020, by and among the Company, Endo International plc, a public limited liability company incorporated in Ireland (“Endo”), and Beta Acquisition Corp., a Delaware corporation and wholly-owned indirect subsidiary of Endo (“Merger Sub”), Merger Sub merged with and into the Company (the “Merger”), with the Company continuing as the surviving company in the Merger and a wholly-owned subsidiary of Endo. In connection with the closing of the Merger, the Company has determined to withdraw the Registration Statement.

No securities covered by the Registration Statement have been issued or sold. Accordingly, the Company hereby respectfully requests that the withdrawal of the Registration Statement be effective as of the date hereof and requests that a written order granting the withdrawal of the Registration Statement be issued by the Commission as soon as reasonably possible.

Please provide Carl Valenstein, Esq. of Morgan, Lewis & Bockius LLP an e-mail copy of the order consenting to the withdrawal of the Registration Statement as soon as it is available at carl.valenstein@morganlewis.com. If you have any questions regarding this application, please contact Mr. Valenstein by telephone at 1.617.341.7501 or by e-mail.

Securities and Exchange Commission

December 2, 2020

Page 2

 

Respectfully,
By:   /s/ Matthew J. Maletta
Name:   Matthew J. Maletta
Title:   Executive Vice President, Chief
  Legal Officer and Secretary